Seldon Capital’s Bristol-Myers Squibb BMY Stock Holding History

Seldon Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-747	Closed	-$53.7K	–	78
2022 Q4	$53.7K	Hold	747	–	–	0.05%	127
2022 Q3	$53K	Hold	747	–	–	0.04%	130
2022 Q2	$58K	Hold	747	–	–	0.03%	133
2022 Q1	$55K	Hold	747	–	–	0.03%	151
2021 Q4	$47K	Buy	+747	New	+$43.8K	0.03%	171

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Seldon Capital's BMY Position: Q1 2023 in Review

Seldon Capital sold out of Bristol-Myers Squibb (BMY) in Q1 2023, closing a stake of 747 shares — an estimated $53.7K sold.

Seldon Capital first reported a position in BMY in Q4 2021 and held it in 5 quarters. The position peaked at $58K in Q2 2022. 2,540 funds tracked by Wall St. Rank hold BMY as of Q1 2023.

Seldon Capital reported no remaining Bristol-Myers Squibb position as of Q1 2023 after selling out during the quarter.
Seldon Capital sold 747 Bristol-Myers Squibb shares in Q1 2023, an estimated $53.7K.
Seldon Capital first reported a position in Bristol-Myers Squibb in Q4 2021 and held it in 5 quarters.
Seldon Capital's Bristol-Myers Squibb position peaked at $58K in Q2 2022.
2,540 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2023.

Based on Seldon Capital's 13F filing for Q1 2023, filed 12 May 2023.